The extent of aortic lymphadenectomy in locally advanced cervical cancer impacts on survival.


Journal

Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 08 06 2020
revised: 11 08 2020
accepted: 20 09 2020
pubmed: 14 11 2020
medline: 18 9 2021
entrez: 13 11 2020
Statut: ppublish

Résumé

The prognostic impact of surgical paraaortic staging remains unclear in patients with locally advanced cervical cancer (LACC). The objective of our study was to evaluate the results of the surgical technique of preoperative aortic lymphadenectomy in LACC related to tumor burden and disease spread to assess its influence on survival. Data of 1,072 patients with cervical cancer were taken from 11 Spanish hospitals (Spain-Gynecologic Oncology Group [GOG] working group). Complete aortic lymphadenectomy surgery (CALS) was considered when the lymph nodes (LNs) were excised up to the left renal vein. The extent of the disease was performed evaluating the LNs by calculating the geometric means and quantifying the log odds between positive LNs and negative LNs. The Kaplan-Meier method was used to estimate the survival distribution. A Cox proportional hazards model was used to account for the influence of multiple variables. A total of 394 patients were included. Pathological analysis revealed positive aortic LNs in 119 patients (30%). LODDS cut-off value of -2 was established as a prognostic indicator. CALS and LODDS <-2 were associated with better disease free survival and overall survival than suboptimal aortic lymphadenectomy surgery and LODDS ≥-2. In a multivariate model analysis, CALS is revealed as an independent prognostic factor in LACC. When performing preoperative surgical staging in LACC, it is not advisable to take simple samples from the regional nodes. Radical dissection of the aortic and pelvic regions offers a more reliable staging of the LNs and has a favorable influence on survival.

Identifiants

pubmed: 33185045
pii: 32.e4
doi: 10.3802/jgo.2021.32.e4
pmc: PMC7767657
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e4

Informations de copyright

Copyright © 2021. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.

Déclaration de conflit d'intérêts

No potential conflict of interest relevant to this article was reported.

Références

J Transl Med. 2018 Nov 26;16(1):326
pubmed: 30477530
Curr Med Sci. 2018 Aug;38(4):567-574
pubmed: 30128863
J Clin Oncol. 2010 Apr 20;28(12):2108-13
pubmed: 20308664
Ann Surg Oncol. 2020 Aug;27(8):2829-2839
pubmed: 32152774
Eur J Obstet Gynecol Reprod Biol. 2019 May;236:79-83
pubmed: 30889424
Cancer. 1999 Apr 1;85(7):1547-54
pubmed: 10193945
Gynecol Oncol. 1999 Dec;75(3):328-33
pubmed: 10600284
Ann Surg Oncol. 2013 Feb;20(2):413-22
pubmed: 22911367
Cancer Res Treat. 2016 Apr;48(2):632-40
pubmed: 26194370
Acta Obstet Gynecol Scand. 2012 Aug;91(8):893-900
pubmed: 22553934
Gynecol Oncol. 2003 Apr;89(1):160-7
pubmed: 12694671
Gynecol Oncol. 2005 Mar;96(3):721-8
pubmed: 15721417
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36
pubmed: 30306584
J Clin Oncol. 2013 Aug 20;31(24):3026-33
pubmed: 23857967
Eur J Surg Oncol. 2018 Oct;44(10):1568-1572
pubmed: 30170883
J Gynecol Oncol. 2020 Jan;31(1):e1
pubmed: 31788991
Bull Cancer. 1979;66(5):503-14
pubmed: 554677
Gynecol Obstet Fertil. 2010 Nov;38(11):668-71
pubmed: 20965771
Gynecol Oncol. 2005 Dec;99(3):536-44
pubmed: 16126259
Int J Gynecol Cancer. 2016 Jan;26(1):169-75
pubmed: 26569062
Gynecol Oncol. 1996 Jul;62(1):19-24
pubmed: 8690286
J Minim Invasive Gynecol. 2017 May - Jun;24(4):609-616
pubmed: 28161495
Cancer Imaging. 2008 Jul 24;8:146-55
pubmed: 18694852
Stat Med. 1992 Jun 15;11(8):1115-29
pubmed: 1496199
Gynecol Oncol. 2002 Feb;84(2):321-6
pubmed: 11812094
Am J Obstet Gynecol. 1979 Apr 1;133(7):814-24
pubmed: 434023
Cancer. 2006 Feb 15;106(4):914-22
pubmed: 16411226
J Minim Invasive Gynecol. 2014 Jan-Feb;21(1):3-8
pubmed: 23911560
Ann Surg Oncol. 2011 Feb;18(2):482-9
pubmed: 20839058
J Gastrointest Surg. 2015 May;19(5):813-20
pubmed: 25560183

Auteurs

Antoni Llueca (A)

Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellón, Department of Medicine, Universitat Jaume I (UJI), Castellón, Spain. antonillueca@gmail.com.

Javier Escrig (J)

Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellón, Department of Medicine, Universitat Jaume I (UJI), Castellón, Spain.

Antonio Gil-Moreno (A)

Department of Gynecologic Oncology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Virginia Benito (V)

Department of Gynecologic Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain.

Alicia Hernández (A)

Department of Gynecology, Hospital Universitario La Paz, Madrid, Spain.

Berta Díaz-Feijoo (B)

Institute Clinic of Gynecology, Obstetrics and Neonatology, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH